Acquired von willebrand syndrome associated with monoclonal gammopathy: A single-center study of 36 patients

Medicine

Volumn 90, Issue 6, 2011, Pages 404-411

  Voisin, Sophie ^a   Hamidou, Mohamed ^b   Lefrançois, Armelle ^c   Sigaud, Marianne ^c   Mahé, Béatrice ^b   Trossaërt, Marc ^c  

^a CHU RANGUEIL   (France)

^b HÔTEL DIEU   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; DESMOPRESSIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; HUMAN; LABORATORY TEST; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; VON WILLEBRAND DISEASE; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; DEAMINO ARGININE VASOPRESSIN; FEMALE; HEMOSTATICS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PARAPROTEINEMIAS; RETROSPECTIVE STUDIES; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 80755189024     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0b013e3182397166     Document Type: Article

References (45)

1. Bayary J, Dasgupta S, Misra N, Ephrem A, Van Huyen JP, Delignat S, Hassan G, Caligiuri G, Nicoletti A, Lacroix-Desmazes S, Kazatchkine MD, Kaveri S. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol. 2006;6:528-534.
2. Coleman R, Favaloro EJ, Soltani S, Keng TB. Acquired von Willebrand disease: potential contribution of the VWF:CB to the identification of functionally inhibiting auto-antibodies to von Willebrand factor. J Thromb Haemost. 2006;4:2085-2088. (Pubitemid 44226802)
3. Collins P, Budde U, Rand JH, Federici AB, Kessler CM. Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia. 2008;14(Suppl 3):49-55. (Pubitemid 351722383)
4. Dietrich G, Pereira P, Algiman M, Sultan Y, Kazatchkine MD. A monoclonal anti-idiotypic antibody against the antigen-combining site of anti-factor VIII autoantibodies defines an idiotope that is recognized by normal human polyspecific immunoglobulins for therapeutic use (IVIg). J Autoimmun. 1990;3:547-557. (Pubitemid 20358953)
5. Eikenboom JC, Tjernberg P, Van Marion V, Heering KJ. Acquired vonWillebrand syndrome: diagnostic problems and therapeutic options. Am J Hematol. 2007;82:55-58. (Pubitemid 46033393)
6. Favaloro EJ. The utility of the PFA-100 in the identification of von Willebrand disease: a concise review. Semin Thromb Hemost. 2006;32:537-545. (Pubitemid 44157393)
7. Federici AB. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol. 2006;43(1 Suppl 1):S48YS58. (Pubitemid 43150500)
8. Federici AB. Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg? J Thromb Haemost. 2008;6:565-568. (Pubitemid 351404922)
9. Federici AB. Therapeutic approaches to acquired von Willebrand syndrome. Expert Opin Invest Drug. 2000;9:347-354. (Pubitemid 30032316)
10. Federici AB. Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome. Hum Immunol. 2005;66:422-430. (Pubitemid 40615799)
11. Federici AB, Budde U, Rand JH. Acquired von Willebrand syndrome 2004: International RegistryVdiagnosis and management from online to bedside. Hamostaseologie. 2004;24:50-55. (Pubitemid 38233047)
12. Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, Lethagen S, Nitu I, Ludwig G, Hilbert L, Mannucci PM. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood. 2004;103:2032-2038. (Pubitemid 38326217)
13. Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood. 1998;92:2707-2711. (Pubitemid 28469082)
14. Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood. 2008;112:250-255.
15. Franchini M, Lippi G. Acquired von Willebrand syndrome: an update. Am J Hematol. 2007;82:368-375. (Pubitemid 46651140)
16. Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neumann C, Trossaert M, Meyer D. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood. 1998;91:1325-1331. (Pubitemid 28086886)
17. Fricke WA, Brinkhous KM, Garris JB, Roberts HR. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody. Blood. 1985;66:562-569. (Pubitemid 15230759)
18. Graff-Dubois S, Siberil S, Elluru S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV. EUse of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders. Transfus Clin Biol. 2007;14:63-68. (Pubitemid 46881135)
19. Grimaldi D, Bartolucci P, Gouault-Heilmann M, Martin-Toutain I, Khellaf M, Godeau B. Rituximab failure in a patient with monoclonal gammopathy of undetermined significance (MGUS)-associated acquired von Willebrand syndrome. Thromb Haemost. 2008;99:782-783. (Pubitemid 351694237)
20. Hayashi T, Yagi H, Suzuki H, Nonaka Y, Nomura T, Sakurai Y, Shibata M, Matsumoto M, Yamamoto Y, Fujimura Y. Low-dosage intravenous immunoglobulin in the management of a patient with acquired von Willebrand syndrome associated with monoclonal gammopathy of undetermined significance. Pathophysiol Haemost Thromb. 2002;32:33-39. (Pubitemid 37490485)
21. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747-755.
22. Kos CA, Ward JE, Malek K, Sanchorawala V, Wright DG, O'Hara C, Connors L, Skinner M, Seldin DC. Association of acquired von Willebrand syndrome with AL amyloidosis. Am J Hematol. 2007;82:363-367. (Pubitemid 46651139)
23. Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand disease. Mayo Clin Proc. 2002;77:181-187. (Pubitemid 34118895)
24. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134:573-589. (Pubitemid 44255500)
25. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol. 2007;139:730-743. (Pubitemid 350115735)
26. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ III. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362-1369.
27. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ III. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569. (Pubitemid 34438817)
28. Luboshitz J, Lubetsky A, Schliamser L, Kotler A, Tamarin I, Inbal A. Pharmacokinetic studies with FVIII/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome. Thromb Haemost. 2001;85:806-809. (Pubitemid 32421812)
29. Mannucci PM, Lombardi R, Bader R, Horellou MH, Finazzi G, Besana C, Conard J, Samama M. Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. Blood. 1984;64:614-621. (Pubitemid 14073478)
30. Mazoyer E, Fain O, Dhote R, Laurian Y. Is rituximab effective in acquired von Willebrand syndrome? Br J Haematol. 2009;144:967-968.
31. Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, Budde U, van Vliet HH. Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications. Semin Thromb Hemost. 2006;32: 577-588. (Pubitemid 44453019)
32. Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A, Kodama F, Okubo T. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood. 1998;91: 3623-3629. (Pubitemid 28225728)
33. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007;27:233-245. (Pubitemid 46790823)
34. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc. 2006;81:693-703.
35. Siaka C, Rugeri L, Caron C, Goudemand J. A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Haemophilia. 2003;9:303-308. (Pubitemid 36622033)
36. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood. 2004;103:4424-4428. (Pubitemid 38745966)
37. Tefferi A, Nichols WL. Acquired von Willebrand disease: concise review of occurrence, diagnosis, pathogenesis, and treatment. Am J Med. 1997;103:536-540. (Pubitemid 28018657)
38. Tiede A, Priesack J, Werwitzke S, Bohlmann K, Oortwijn B, Lenting P, Eisert R, Ganser A, Budde U. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost. 2008;6:569-576. (Pubitemid 351404923)
39. van Genderen PJ, Michiels JJ. Acquired von Willebrand disease. Baillieres Clin Haematol. 1998;11:319-330. (Pubitemid 29103547)
40. van Genderen PJ, Michiels JJ, Bakker JJ, van 't Veer MB. Effectiveness of high-dose intravenous gamma globulin therapy in acquired von Willebrand's disease. Vox Sang. 1994;67:14-17. (Pubitemid 24206497)
41. van Genderen PJ, Michiels JJ, van der Poel-van de Luytgaarde SC, van Vliet HH. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Ann Hematol. 1994;69:81-84. (Pubitemid 24266968)
42. van Genderen PJ, Terpstra W, Michiels JJ, Kapteijn L, van Vliet HH. High-dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease. Thromb Haemost. 1995;73:891-892.
43. van Genderen PJ, Vink T, Michiels JJ, van 't Veer MB, Sixma JJ, van Vliet HH. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood. 1994;84: 3378-3384. (Pubitemid 24352900)
44. Varettoni M, Corso A, Cocito F, Mangiacavalli S, Pascutto C, Zappasodi P, Pica G, Lazzarino M. Changing pattern of presentation in monoclonal gammopathy of undetermined significance: a single-center experience with 1400 patients. Medicine (Baltimore). 2010;89:211-216.
45. Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, Weksler BB, Schechter GP. Rituximab in the treatment of acquired factor VIII inhibitors. Blood. 2002;100:3426-3428. (Pubitemid 35217098)